Andere Sprachen Devyser Diagnostics AB

Aktien

A3C811

SE0016588867

DVYSR

Markt geschlossen - Nasdaq Stockholm Andere Börsenplätze 17:24:44 02.05.2024			% 5 Tage	% 1. Jan.
99,4 ^SEK	+0,61 %		-4,42 %	+26,46 %

25.04.	Devyser erhält IVDR-Zulassung für Software zur Post-Transplantationsüberwachung	CI
11.03.	Devyser Diagnostics AB erzielt mit dem Mukoviszidose-NGS-Test einen Durchbruch in den USA	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Devyser Receives IVDR Approval for Post-Transplant Monitoring Software	25.04.
Devyser partners with Hamilton to automate laboratory NGS workflows	23.04.
Devyser receives MDSAP certification for Brazil	16.04.
Devyser Diagnostics AB Achieves Breakthrough in the US with Cystic Fibrosis NGS Test	11.03.
Devyser announces study publication demonstrating dd-cfDNA detection in dual donor kidney transplant patient	29.02.
Devyser Diagnostics AB Announces Study Publication Demonstrating dd-cfDNA Detection in Dual Donor Kidney Transplant Patient	29.02.
Devyser Diagnostics Q4 - Better positioned than ever	21.02.
Devyser Diagnostics AB publishes year-end report for January to December 2023	20.02.
Devyser Diagnostics AB Reports Earnings Results for the Full Year Ended December 31, 2023	20.02.
Devyser Diagnostics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	20.02.
Invitation to audiocast for Devyser’s Q4 report 2023	14.02.
Devyser Diagnostics AB Announces Michael Uhlin, CSO Joins Management Team as of February 1, 2024	29.01.
Devyser's US Lab Inks SEK25 Million Deal with UK Diagnostics Company Cyted	17.01.
Devyser Genomic Laboratories Signs First Commercial Agreement with Cyted	17.01.
Sweden’s Devyser Wins SEK1.5 Million Tender in Italy for Cystic Fibrosis Test Kits	15.01.
Devyser Diagnostics AB Wins Tender for Cystic Fibrosis in Italy	15.01.
Devyser Diagnostics Teams Up with Illumina to Offer IVD Tests in Europe, US	08.01.
Devyser signs in vitro diagnostic agreement with Illumina to broaden access to its tests	08.01.
Devyser Diagnostics AB Signs in Vitro Diagnostic Agreement with Illumina to Broaden Access to Its Tests	08.01.
Sweden’s Devyser Wins $6 Million Tender for Cystic Fibrosis Diagnostic Tool in Italy	11.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Devyser Diagnostics AB

Aktien

A3C811

SE0016588867

DVYSR

Andere Sprachen

Filter